• ATRX Loss Sensitizes High-Grade Glioma to RTK and PDGFR Inhi

  2026-04-22

  This study demonstrates that high-grade glioma cells deficient in ATRX display heightened sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors. The work also reveals that combining these inhibitors with temozolomide yields enhanced toxicity specifically in ATRX-mutant backgrounds, suggesting a targeted therapeutic opportunity in glioma treatment.

• Clarithromycin as a CYP3A Inhibitor: A New Standard for Quan

  2026-04-22

  Explore how Clarithromycin, a potent CYP3A inhibitor, underpins rigorous, quantitative drug-drug interaction research beyond traditional cardiovascular applications. This in-depth analysis reveals advanced assay design considerations and how Clarithromycin’s properties enable new frontiers in pharmacokinetic studies.

• MCL-1 Inhibitor A-1210477: Precision Tools for Apoptosis Res

  2026-04-21

  Explore the scientific basis and advanced applications of MCL-1 inhibitor A-1210477 in dissecting apoptosis induction in cancer cells. This article uniquely integrates mechanistic insights, assay strategies, and critical analysis of current research to inform high-impact experimental design.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-04-21

  Vijayan and Gourinath's 2021 study applied structure-based virtual screening and molecular dynamics to identify potent natural product inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. Their findings highlight thymopentin and oleuropein as promising NSP15 inhibitors, underscoring NSP15's therapeutic potential in COVID-19 intervention.

• Minocycline HCl (SKU B1791): Data-Driven Solutions for Assay

  2026-04-20

  This article delivers a scenario-driven, evidence-backed exploration of how Minocycline HCl (SKU B1791) from APExBIO addresses core laboratory challenges in cell viability, proliferation, and cytotoxicity assays. By integrating real-world workflow dilemmas and peer-reviewed findings, it demonstrates how Minocycline HCl enables reproducible, reliable results critical for inflammation and neurodegeneration research.

• Nirmatrelvir (PF-07321332): Empowering Translational COVID-1

  2026-04-20

  This thought-leadership article explores the mechanistic underpinnings and translational strategy behind Nirmatrelvir (PF-07321332), a potent SARS-CoV-2 3CL protease inhibitor. It provides actionable guidance for researchers targeting coronavirus replication, referencing both recent peer-reviewed studies and competitive landscapes, and highlights how APExBIO’s high-purity offering enables reproducible, next-generation antiviral research.

• Unraveling Lipid Peroxidation Dynamics with the MDA Assay Ki

  2026-04-19

  Explore the scientific depth and translational power of the Lipid Peroxidation (MDA) Assay Kit for malondialdehyde quantification. This article uniquely analyzes mechanistic insights from ferroptosis research and offers advanced protocols to elevate oxidative stress biomarker studies.

• Ornithine Cycle Disruption Drives Realgar-Induced CNS Toxici

  2026-04-18

  This study uncovers how realgar-derived arsenic disrupts the hepatic ornithine cycle, leading to ornithine accumulation and downstream inhibition of astrocyte glycolysis via ZBTB7A activation, culminating in central nervous system (CNS) toxicity. The work provides mechanistic insights into the liver–brain metabolic axis and highlights targets for mitigating arsenic-induced neurotoxicity.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-17

  Schwartz’s dissertation presents a critical re-evaluation of in vitro drug response metrics in cancer, distinguishing between proliferative arrest and cell death effects. By clarifying these measurement nuances, the work guides improved experimental design and interpretation, especially for targeted agents and checkpoint inhibitors.

• Baicalin and KEAP1-NRF2/HO-1 Pathway Modulation in Bench Res

  2026-04-16

  Baicalin unlocks new experimental possibilities by modulating KEAP1-NRF2/HO-1 and TGF-β1/p-Smad3 pathways, making it a cornerstone for neuroplasticity and oncology research. Its robust solubility profile and assay-validated efficacy offer researchers a high degree of workflow flexibility and reproducibility.

• Rucaparib (AG-014699): Precision in DNA Damage Response Rese

  2026-04-15

  Rucaparib (AG-014699) empowers cancer biology labs to dissect DNA repair mechanisms, specifically enhancing radiosensitization in PTEN-deficient and ETS fusion-expressing prostate cancer models. This article provides evidence-driven workflows, troubleshooting guidance, and actionable protocol parameters to maximize reproducibility and sensitivity in DNA damage response studies.

• TAK-715: Precision p38 MAPK Inhibitor for Inflammation Resea

  2026-04-14

  TAK-715 empowers researchers to precisely dissect p38α MAPK signaling in chronic inflammatory disease models, unlocking advanced mechanistic studies and translational breakthroughs. Its nanomolar potency, high selectivity, and unique dual-action potential set it apart for robust anti-inflammatory agent development.

• Phosbind Acrylamide: Enhancing Phosphorylation Analysis Work

  2026-04-13

  Phosbind Acrylamide enables high-resolution, antibody-free detection of phosphorylation-dependent protein mobility shifts in SDS-PAGE, transforming signal transduction research. This article details real lab protocols, troubleshooting strategies, and interprets new mechanistic advances from recent metastasis studies.

• Biomimetic Chromatography for Modeling Lung Drug Permeabilit

  2026-04-13

  This study rigorously evaluates biomimetic open tubular capillary electrochromatography (OT-CEC) and immobilised artificial membrane liquid chromatography (IAM-LC), both coupled to mass spectrometry, for modeling pulmonary drug permeability. The findings highlight the strengths and limitations of these advanced chromatographic techniques in supporting high-throughput screening and lead optimization for drug development.

• Wortmannin: Precision PI3K Inhibition for Translational Impa

  2026-04-12

  This article explores the mechanistic underpinnings and strategic deployment of Wortmannin—a potent, selective, and irreversible PI3K inhibitor—for translational researchers. By integrating peer-reviewed mechanistic studies, recent advances in host-pathogen research, and practical workflow guidance, we reveal how APExBIO’s Wortmannin (SKU: A8544) enables high-impact experiment design in cancer, autophagy, and antiviral research. We highlight new directions made possible by cross-domain evidence, with a focus on reproducibility and translational value.

11352 records 1/757 page Next 12345 下5页 Last page